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journal homepage: www.e lsev ier .com/ locate / j j ccLetters to the EditorIs the level of resistin appropriate for predicting
atrial ﬁbrillation?We read the paper entitled ‘‘Increased level of resistin predicts
development of atrial ﬁbrillation’’ by Ozcan et al. [1] with interest.
These authors stated that plasma resistin and the high sensitivity
C-reactive protein levels were the only independent predictors of
atrial ﬁbrillation (AF) and that elevated levels of plasma resistin
were related to the paroxysmal AF group and the persistent AF
group, but not to the permanent AF group.
Although several risk factors have been identiﬁed for the
development of AF, the pathogenesis is multifactorial and not
totally understood. Different factors are included in this self-
perpetuating process such as volume and/or pressure overload in
the heart, ﬁbrosis, oxidative stress, and inﬂammation. Since cardiac
inﬂammatory disorders such asmyocarditis, pericarditis, and post-
periocardiotomy syndrome frequently are accompanied by AF,
clinicians concentrate upon the idea that AF is closely associated
with inﬂammation according to these clinical observations [2].
Previously, inﬂammatory markers have been assessed in the
cardiac tissue, intracardiac blood, and peripheral blood in patients
with AF. Furthermore, in one study, higher C-reactive protein (CRP)
and interleukin-6 levelswere detected in the left atrium than in the
coronary sinus during AF and the authors concluded that there
appears to be intracardiac sequestration of inﬂammatory cyto-
kines, potentially pointing to an important mechanism of atrial
remodeling [3]. However, if the blood samples of this study had
been collected from left atrium or coronary sinus, results different
from that study could have been obtained, and especially the atrial
inﬂammation could be more accurately evaluated.
The authors also stated that the permanent AF was associated
with higher levels of CRP than paroxysmal AF, implying that CRP
levels may be related to the burden of AF, but the same thing is not
valid for resistin levels. The reason for these results may be due to
the small number of patients included in the study as well as drug
usage. Namely, circulating resistin levels are found to be decreased
by the anti-diabetic drug rosiglitazone [4]. Moreover, reduced
circulating resistin levels after rosiglitazone treatment have been
reported by Moore et al. [5]. If the detailed history of drug usage of
the patient population had been questioned, different results
might have been obtained.
Furthermore, inﬂammation appears to play an important role in
the development of thromboembolic complications associated
with AF. The relationship between inﬂammation and AF-related
thromboembolism was supported by the observation in which
interleukin-6 and CRP are markedly elevated in patients with
dilated left atrium and an inadequately functioning left atrial
appendage. Moreover, CRP has also been shown to be correlated
with identiﬁed clinical stroke risk stratiﬁcation schemas (CHADS2,0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsSPAF) [6]. In the current study, it was not speciﬁed whether any
thromboembolic events occurred in the one-year follow-up or if
therewas any relationshipwith predeﬁned risk scores. The relation
of the resistin levels with these factors should have been important
in the prediction of thromboembolic events.
Finally, we would like to have much more detailed information
from the authors of this study regarding drug usage and occurrence
of thromboembolic events in follow-up. It would be much more
accurate if they had collected the blood samples from the coronary
sinus or left atrium. According to the results of this study, we think
that plasma resistin levelsmay not be an appropriatemarker in the
prediction of the development of AF. To clarify this issue, further
large-scale studies are needed.References
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